datopotamab deruxtecan   Click here for help

GtoPdb Ligand ID: 13304

Synonyms: Dato-DXd | datopotamab deruxtecan-dlnk | Datroway® | DS-1062 | DS-1062a
Approved drug
datopotamab deruxtecan is an approved drug (FDA (2025))
Compound class: Antibody
Comment: Datopotamab deruxtecan is an anti-TROP2 (TACSTD2) antibody drug conjugate (ADC). The cytotoxic payload is an exatecan-derived topoisomerase I inhibitor known as deruxtecan (DXd/MAAA1181a; PubChem CID 118305111). The ADC is highly stable in circulation and the DXd is only cleaved once inside cells where it induces DNA damage and apoptosis.

Overexpression of TROP2 is oncogenic and drives proliferation in cancer cells.
References
1. Schipilliti FM, Drittone D, Mazzuca F, La Forgia D, Guven DC, Rizzo A. (2024)
Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer.
Heliyon, 10 (7): e28385. [PMID:38560142]